Analystreport

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target raised by analysts at Cantor Fitzgerald from $5.00 to $8.00. They now have an "overweight" rating o

Corvus Pharmaceuticals, Inc.  (CRVS) 
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: corvuspharma.com